Noncoding RNA: novel regulators and potential targets of the PI3K/AKT pathway in thyroid cancer

doi:10.3877/cma.j.issn.1674-0793.2026.05.010

Abstract

Abstract:

Thyroid cancer (TC) is one of the most common endocrine malignancies, showing rapidly increasing incidence. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway is a crucial pathway that interacts with various key cell signaling molecules. It is responsible for a wide range of cellular activities in TC, including cell proliferation, apoptosis, invasion, metastasis and epithelial-mesenchymal transition. In addition, the PI3K/AKT pathway also plays a crucial role in the response to TC ¹³¹I therapy. Researches have shed light on the significant role of noncoding RNAs (ncRNAs), which include microRNA (miRNA), long noncoding RNA (lncRNA), and circular RNA (circRNA), in regulating key signaling pathways, including the PI3K/AKT pathway. Conversely, PI3K/AKT also regulates the expression of ncRNA. Therefore, this review aims to comprehensively discuss the pivotal role of ncRNAs in regulating the PI3K/AKT pathway, as well as their roles in the biological functions of TC. In addition, we also attempt to elucidate the complex feedback loops that exist between these components.

Key words: Thyroid neoplasms, Noncoding RNA, PI3K-Akt pathway, MiRNAs, RNA, long noncoding, RNA, circular

Ruining Cao, Haoqiang Jing, Yuhan Zhang, Ri Sa. Noncoding RNA: novel regulators and potential targets of the PI3K/AKT pathway in thyroid cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2026, 20(05): 346-351.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2026.05.010

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2026/V20/I05/346

Figures/Tables 3

References 36

［1］	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209–249.
［2］	Li Z, Lv D, Niu L, et al. The role of WNT signaling in papillary thyroid cancer: mechanisms, epigenetic regulation, therapeutic resistance, and emerging clinical strategies[J]. Pathol Res Pract, 2025, 275: 156231.
［3］	He Y, Sun MM, Zhang GG, et al. Targeting PI3K/Akt signal transduction for cancer therapy[J]. Sig Transduct Target Ther, 2021, 6(1): 425.
［4］	Voinea IA, Petrova E, Dumitru N, et al. Pathogenesis and management strategies in radioiodine-refractory differentiated thyroid cancer: from molecular mechanisms toward therapeutic approaches: A comprehensive review[J]. J Clin Med, 2024, 13(23): 7161.
［5］	Drilon A, Hu ZI, Lai GGY, et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes[J]. Nat Rev Clin Oncol, 2018, 15(3): 151–167.
［6］	Lan Y, Liu D, Liang B, et al. ITGA3-MET interaction promotes papillary thyroid cancer progression via ERK and PI3K/AKT pathways[J]. Ann Med, 2025, 57(1): 2483379.
［7］	Yehia L, Keel E, Eng C. The clinical spectrum of PTEN mutations[J]. Annu Rev Med, 2020, 71: 103–116.
［8］	Salim U, Kumar A, Kulshreshtha R, et al. Biogenesis, characterization, and functions of mirtrons[J]. Wires RNA, 2022, 13(1): e1680.
［9］	Han J, Zhang M, Nie C, et al. MiR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1[J]. Cell Death Dis, 2019, 10(3): 195.
［10］	Bu Q, You F, Pan G, et al. MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD[J]. Biomed Pharmacother, 2017, 88: 443–448.
［11］	Boufraqech M, Zhang L, Jain M, et al. MiR-145 suppresses thyroid cancer growth and metastasis and targets AKT3[J]. Endocr Relat Cancer, 2014, 21(4): 517–531.
［12］	Tan J, Li C, Ren L, et al. miR-451a suppresses papillary thyroid cancer cell proliferation and invasion and facilitates apoptosis through targeting DCBLD2 and AKT1[J]. Mol Cell Probes, 2022, 66: 101863.
［13］	Li J, Zhang Z, Hu J, et al. miR-1246 regulates the PI3K/AKT signaling pathway by targeting PIK3AP1 and inhibits thyroid cancer cell proliferation and tumor growth[J]. Mol Cell Biochem, 2022, 477(3): 649–661.
［14］	Ramírez-Moya J, Wert-Lamas L, Santisteban P. microRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN[J]. Oncogene, 2018, 37(25): 3369–3383.
［15］	Huang Y, Yu S, Cao S, et al. MicroRNA-222 promotes invasion and metastasis of papillary thyroid cancer through targeting protein phosphatase 2 regulatory subunit B alpha expression[J]. Thyroid, 2018, 28(9): 1162–1173.
［16］	Montero-Conde C, Graña-Castro O, Martín-Serrano G, et al. Hsa-miR-139–5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing[J]. Int J Cancer, 2020, 146(2): 521–530.
［17］	Zheng T, Zhou Y, Xu X, et al. MiR-30c-5p loss-induced PELI1 accumulation regulates cell proliferation and migration via activating PI3K/AKT pathway in papillary thyroid carcinoma[J]. J Transl Med, 2022, 20(1): 20.
［18］	Tang Y, Wang J, Lian Y, et al. Linking long non-coding RNAs and SWI/SNF complexes to chromatin remodeling in cancer[J]. Mol Cancer, 2017, 16(1): 42.
［19］	Feng J, Zhou Q, Yi H, et al. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145–5p to regulate AKT3[J]. Cell Death Dis, 2019, 10(6): 433.
［20］	Du X, Hao Y, Liu M, et al. LncRNA HOTAIR promotes cell proliferation and migration in papillary thyroid carcinoma cells by sponging miR-206/c-Met axis[J]. J Mol Histol, 2025, 56(5): 283.
［21］	Wen J, Wang H, Dong T, et al. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301–3p/STAT3 axis and PI3K/AKT signalling pathway[J]. Cell Prolif, 2019, 52(2): e12569.
［22］	Du P, Liu F, Liu Y, et al. Linc00210 enhances the malignancy of thyroid cancer cells by modulating miR-195–5p/IGF1R/Akt axis[J]. J Cell Physiol, 2020, 235(2): 1001–1012.
［23］	Zhang L, Zhang J, Li S, et al. Genomic amplification of long noncoding RNA HOTAIRM1 drives anaplastic thyroid cancer progression via repressing miR-144 biogenesis[J]. RNA Biol, 2021, 18(4): 547–562.
［24］	Hejazi M, Jafari T, Yari A, et al. A novel long non-coding RNA, PICSAR, promotes thyroid cancer progression through the hsa-miR-320A/hsa-miR-485/RAPGEFL1 axis[J]. Med Oncol, 2025, 42(10): 448.
［25］	Chen W, Yu J, Xie R, et al. Roles of the SNHG7/microRNA-9–5p/DPP4 CeRNA network in the growth and ¹³¹I resistance of thyroid carcinoma cells through PI3K/Akt activation[J]. Oncol Rep, 2021, 45(4): 3.
［26］	Li L, Lin X, Xu P, et al. LncRNA GAS5 sponges miR-362–5p to promote sensitivity of thyroid cancer cells to ¹³¹I by upregulating SMG1[J]. IUBMB Life, 2020, 72(11): 2420–2431.
［27］	Liu H, Deng H, Zhao Y, et al. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling[J]. J Exp Clin Cancer Res, 2018, 37(1): 279.
［28］	Duan Y, Wang Z, Xu L, et al. LncRNA SNHG3 acts as a novel tumor suppressor and regulates tumor proliferation and metastasis via AKT/mTOR/ERK pathway in papillary thyroid carcinoma[J]. J Cancer, 2020, 11(12): 3492–3501.
［29］	Li Z, Gao Y, Li L, et al. Curcumin inhibits papillary thyroid cancer cell proliferation by regulating lncRNA LINC00691[J]. Anal Cell Pathol, 2022, 2022: 5946670.
［30］	Wang Y, Dzakah EE, Wang X. Molecular basis of backsplicing regulation and its application to manipulate circRNA levels[J]. RNA Biol, 2025, 22(1): 1–10.
［31］	Han P, Chen G, Zhang Q, et al. Circ_PSD3 stimulates cell proliferation, migration, invasion and epithelial to mesenchymal transition (EMT) in papillary thyroid carcinoma via the regulation of miR-145–5p/miR-338–3p/HMGB3 axis[J]. J Biochem Mol Toxicol, 2025, 39(8): e70402.
［32］	Dong LP, Chen LY, Bai B, et al. Circ_0067934 promotes the progression of papillary thyroid carcinoma cells through miR-1301–3p/HMGB1 axis[J]. Neoplasma, 2022, 69(1): 1–15.
［33］	Zheng H, Fu Q, Ma K, et al. Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling[J]. Endocr J, 2021, 68(11): 1247–1266.
［34］	Chen L, Zhuo D, Yuan H. Circ_100395 impedes malignancy and glycolysis in papillary thyroid cancer: involvement of PI3K/AKT/mTOR signaling pathway[J]. Immunol Lett, 2022, 246: 10–17.
［35］	Shu C, Wang S, Hu J, et al. CircNDST1 promotes papillary thyroid cancer progression via its interaction with CSNK2A1 to activate the PI3K-Akt pathway and epithelial–mesenchymal transition[J]. J Endocrinol Investig, 2023, 46(3): 545–557.
［36］	Zhou T, Li Z, Huang W, et al. Genome-wide analyses identify circAQR, a circular RNA suppressing proliferation but promoting migration and invasion in thyroid cancer[J]. NPJ Precis Oncol, 2025, 9(1): 171.

[1]	Qi Liu, Ning Gu, Ling Yang, Yan Zhou, Yanjing Rui, Yimin Dai. Clinical characteristics and maternal-fetal outcomes of pregnancy complicated by malignancy [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2025, 21(06): 634-642.
[2]	Wenyong Luo, Wenlong Huang, Qintong Ruan, Ying Cai, Xin Wang, Zhuguo Wu, Liling Wang, Haibing Yu. Construction of risk prediction models for postoperative hypocalcemia in thyroid cancer patients [J]. Chinese Archives of General Surgery(Electronic Edition), 2026, 20(04): 257-264.
[3]	Min Liu, Jingzhu Zhao, Xiukun Hou, Miao Zhang, Xiaocan Wu, Xiangqian Zheng. Expression characteristics and clinical significance of SF3B5 in papillary thyroid carcinoma and its molecular mechanisms in inhibiting tumor progression [J]. Chinese Archives of General Surgery(Electronic Edition), 2026, 20(02): 103-111.
[4]	Tinglin Yang, Tao Huang. Progress and challenges in the application of artificial intelligence for evaluating thyroid nodules [J]. Chinese Archives of General Surgery(Electronic Edition), 2026, 20(01): 60-65.
[5]	Yu Zhang, Xiaotian Xia, Minggao Guo, Youben Fan. Comparison of the effects of two surgical procedures in treating thyroid micro-papillary carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2026, 20(05): 480-484.
[6]	Zhao Han, Kejian Zhang, Ana Nie, Jianhong Zhao, Xiaowu Li, Xiaoli Chen, Wei Hu, Wei Zhang, Yang Li, Xue Yang. 3D endoscopic thyroidectomy with precise dissection of the extralaryngeal multiple branches of the recurrent laryngeal nerve: A case report [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2026, 20(03): 305-306.
[7]	Guangze Sun, Yongqiang Yao, Jiping Xie, Yi Wan, Shiyu Yang, Min Zhang, Yuchuan Ge, Chuning Zhang. The application of the recurrent laryngeal nerve tunneling technique in endoscopic thyroid surgery via the anterior oral cavity and submental approach [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2026, 20(02): 203-204.
[8]	Qingyu Chang, Chengcheng Feng, Xuemin Liu, Yikun Jiang, Haiqiang Wang, Chang Yao. The application of non-inflatable subclavian approach endoscopic radical thyroidectomy in papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2026, 20(02): 195-198.
[9]	Kai Liu, Wenjie Dai. Prevention and treatment measures for chylous fistula after cervical lymph node dissection for thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2026, 20(01): 87-90.
[10]	Xiaobei Wang, Qingfu Lv, Ting Ni. Clinical comparison of gasless axillary approach and total areola approach in endoscopic radical resection of thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(04): 368-371.
[11]	Yaojun Zhai, Pisong Li, Hongqing Zhao. Evaluation of thyroid function following endoscopic unilateral thyroidectomy via transareolar approach [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 329-332.
[12]	Yunlong Li, Xuliang Xia, Wei Liu, Zhiqiang Jiang, Li Tang, Kai Liu, Haozhong Liu, Siyuan Zhang. Comparison of microwave ablation and TOET in the treatment of T1N0M0 stage papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 341-344.
[13]	Jiaxu Dong, Meizi Song, Xun Bi. Effect and survival prognosis of radiofrequency ablation combined with TSH suppression in the treatment of papillary thyroid microcarcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 200-203.
[14]	Jian Sun, Minghui Zhao, Enchun Zhao, Weichen Liu. Clinical observation of transthoracic approach endoscopic surgery for thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 204-207.
[15]	Yawen Guo, Qiao Hu, Chaowang Huang, Jing Zhang, Dan Wang, Peng Zhao, Xiaolong Chen, Mingdong Hu. Analysis of the differential expression of miRNAs in elderly patients with bacterial pneumonia using a transcriptomics-based approach [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(04): 521-526.

Please choose a citation manager

Content to export